The endocannabinoid system: Physiology and pharmacology

Alcohol and Alcoholism

Volumn 40, Issue 1, 2005, Pages 2-14

  de Fonseca, Fernando Rodríguez ^a,b   del Arco, Ignacio ^a   Bermudez Silva, Francisco Javier ^a   Bilbao, Ainhoa ^a   Cippitelli, Andrea ^a   Navarro, Miguel ^b  

^a Hospital University Carlos Haya de Málaga   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N MORPHOLINO 1H PYRAZOLE 3 CARBOXAMIDE; 2 ARACHIDONOYLGLYCEROL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 4 [6 METHOXY 2 (4 METHOXYPHENYL) 3 BENZOFURANYLCARBONYL]BENZONITRILE; 5 (4 BROMOPHENYL) 1 (2,4 DICHLOROPHENYL) 4 ETHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; ACYLGLYCEROL LIPASE; ANANDAMIDE; ARACHIDONIC ACID; ARACHIDONIC ACID DERIVATIVE; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; DEXANABINOL; DOPAMINE; ENDOCANNABINOID; FATTY ACID AMIDASE; G PROTEIN COUPLED RECEPTOR; ICOSANOID; LH 21; METHANANDAMIDE; N (3 FURYLMETHYL)ARACHIDONAMIDE; N (4 HYDROXYPHENYL)ARACHIDONAMIDE; PYRAZOLE DERIVATIVE; RIMONABANT; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRODHAMINE;

ALCOHOLISM; ANXIETY DISORDER; ARTICLE; AUTONOMIC NERVOUS SYSTEM; BRAIN FUNCTION; CELL FUNCTION; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG ANTAGONISM; DRUG DEPENDENCE; DRUG RECEPTOR BINDING; DRUG TARGETING; EMOTIONAL DISORDER; GABAERGIC TRANSMISSION; HUMAN; ICOSANOID METABOLISM; IMMUNE SYSTEM; IMMUNOMODULATION; LIPID ANALYSIS; LIPID DEGRADATION; LIPID TRANSPORT; LIPOGENESIS; MENTAL DISEASE; MICROCIRCULATION; MULTIPLE SCLEROSIS; NEUROANATOMY; NEUROLOGIC DISEASE; NEUROMODULATION; NONHUMAN; OBESITY; PAIN; PATHOPHYSIOLOGY; POSTSYNAPTIC POTENTIAL; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; SYSTEMATIC REVIEW; VERTEBRATE;

ALCOHOLISM; ANIMALS; ARACHIDONIC ACIDS; AUTONOMIC NERVOUS SYSTEM; CANNABINOIDS; COGNITION; EMOTIONS; ENDOCANNABINOIDS; HOMEOSTASIS; HUMANS; MESENCEPHALON; MOTIVATION; MOTOR ACTIVITY; POLYUNSATURATED ALKAMIDES; RECEPTORS, CANNABINOID;

CANNABIS; VERTEBRATA;

EID: 12544250727     PISSN: 07350414     EISSN: None     Source Type: Journal    
DOI: 10.1093/alcalc/agh110     Document Type: Article

References (140)

1. Basavarajappa, B. S., Cooper, T. B. and Hungund, B. L. (1998) Chronic ethanol administration down-regulates cannabinoid receptors in mouse brain synaptic plasma membrane. Brain Research 793, 212-218.
2. Basavarajappa, B. S. and Hungund, B. L. (1999) Chronic ethanol increases the cannabinoid receptor agonist anandamide and its precursor N-arachidonoylphosphatidyl-ethanolamine in SK-N-SH cells. Journal of Neurochemistry 72, 522-528.
3. Basavarajappa, B. S., Saito, M., Cooper, T. B. and Hungund, B. L. (2000) Stimulation of cannabinoid receptor agonist 2-arachidonylglycerol by chronic ethanol and its modulation by specific neuromodulators in cerebellar granule neurons. Biochimica et Biophysica Acta 1535, 78-86.
4. Batkai, S., Jarai, Z., Wagner, J. A. et al. (2001) Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nature Medicine 7, 827-832.
5. Beltramo, M., Stella, N., Calignano, A., Lin, S. Y., Makriyannis, A. and Piomelli, D. (1997) Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science 277, 1094-1097.
6. Beinfeld, M. C. and Connolly, K. (2001) Activation of CB1 cannabinoid receptors in rat hippocampal slices inhibits potassium-evoked cholecystokinin release, a possible mechanism contributing to the spatial memory defects produced by cannabinoids. Neuroscience Letters 301, 69-71.
7. Bisogno, T., Howell, F., Williams, G. et al. (2003) Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signalling in the brain. Journal of Cell Biology 163, 463-468.
8. Boger, D. L., Sato, H., Lerner, A. E. et al. (2000) Exceptionally potent inhibitors of fatty acid amide hydrolase: the enzyme responsible for degradation of endogenous oleamide and anandamide. Proceedings of the National Academy of Sciences of the United States of America 97, 5044-5049.
9. Bouaboula, M., Perrachon, S., Milligan, L. et al. (1997) A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions. Journal of Biological Chemistry 272, 22330-22339.
10. Breivogel, C. S. and Childers, S. R. (1998) The functional neuroanatomy of brain cannabinoid receptors. Neurobiology of Disease 5, 417-431.
11. 35S]GTPγS binding to rat cerebellar membranes correlates with agonist-induced decreases in GDP affinity. Journal of Biological Chemistry 273 16865-16873.
12. Cadas, H., Gaillet, S., Beltramo, M., Venance, L. and Piomelli, D. (1996) Biosynthesis of an endogenous cannabinoid precursor in neurons and its control by calcium and cAMP. Journal of Neuroscience 16, 3934-3942.
13. Cabral, G. A. (2001) Marijuana and cannabinoids: effects on infections, immunity and AIDS. Journal of Cannabis Therapeutics 1, 61-85.
14. Calignano, A., La Rana, G., Giuffrida, A. and Piomelli, D. (1998) Control of pain initiation by endogenous cannabinoids. Nature 394, 277-281.
15. Calignano, A., La Rana, G., Loubet-Lescoulie, P. and Piomelli, D. (2000) A role for the endogenous cannabinoid system in the peripheral control of pain initiation. Progress in Brain Research 129, 471-482.
16. Casanova, M. L., Blazquez, C., Martinez-Palacio, J., Villanueva, C., Fernandez-Acenero, M. J., Huffman, J. W., Jorcano, J. L. and Guzman, M. (2003) Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. Journal of Clinical Investigation 111, 43-50.
17. Castellano, C., Rossi-Arnaud, C., Cestari, V. and Costanzi, M. (2003) Cannabinoids and memory: animal studies. Current Drug Targets - CNS & Neurological Disorders 2, 389-402.
18. Chaperon, F. and Thiébot, M.-H. (1999) Behavioral effects of cannabinoid agents in animals. Critical Reviews in Neurobiology 13 243-281.
19. Chevaleyre, V. and Castillo, P. E. (2003) Heterosynaptic LTD of hippocampal GABAergic synapses: a novel role of endocannabinoids in regulating excitability. Neuron 38, 461-472.
20. Childers, S. R. and Deadwyler, S. A. (1996) Role of cyclic AMP in the actions of cannabinoid receptors. Biochemical Pharmacology 52, 819-827.
21. Colombo, G., Agabio, R., Fa, M., Guano, L., Lobina, C., Loche, A., Reali, R. and Gessa, G. L. (1998) Reduction of voluntary ethanol intake in ethanol-preferring sP rats by the cannabinoid antagonist SR-141716. Alcohol and Alcoholism 33, 126-130.
22. Colombo, G., Serra, S., Brunetti, G., Gómez, R., Melis, S., Vacca, G., Carai, M. M., and Gessa, G. L. (2002) Stimulation of voluntary ethanol intake by cannabinoid receptor agonists in ethanol-preferring sP rats. Psychopharmacology 159, 181-187.
23. Comings, D. E., Muhleman, D., Gade, R., Johnson, P., Verde, R., Saucier, G., and MacMurray, J. (1997) Cannabinoid receptor gene (CNR1): association with i.v. drug use. Molecular Psychiatry 2 161-168.
24. Cravatt, B. F., Demarest, K., Patricelli, M. P., Bracey, M. H., Giang, D. K., Martin, B. R. and Lichtman, A. H. (2001) Supersensitivity to anandamide and enhanced endogenous cannabinoid signalling in mice lacking fatty acid amide hydrolase. Proceedings of the National Academy of Sciences of the United States America 98 9371-9376.
25. Cravatt, B. F., Giang, D. K., Mayfield, S. P., Boger, D. L., Lerner, R. A., and Gilula, N. B. (1996) Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384, 83-87.
26. Cravatt, B. F. and Lichtman, A. H. (2003) Fatty acid amide hydrolase: an emerging therapeutic target in the endocannabinoid system. Current Opinion in Chemical Biology 7, 469-475.
27. De Lago, E., Fernandez-Ruiz, J., Ortega-Gutierrez, S., Viso, A., Lopez-Rodriguez, M. L. and Ramos, J. A. (2002) UCM707, a potent and selective inhibitor of endocannabinoid uptake, potentiates hypokinetic and antinociceptive effects of anandamide. European Journal of Pharmacology 449, 99-103.
28. De Petrocellis, L., Cascio, M. G. and Di Marzo, V. (2004) The endocannabinoid system: a general view and latest additions. British Journal of Pharmacology 141, 765-774.
29. Derkinderen, P., Toutant, M., Burgaya, F., Le Bert, M., Siciliano, J. C., De Franciscis, V., Gelman, M. and Girault, J. A. (1996) Regulation of a neuronal form of focal adhesion kinase by anandamide. Science 273, 1719-1722.
30. Devane, W. A., Dysarz, F. A. 3rd, Johnson, M., Melvin, L. S. and Howlett, A. C. (1988) Determination and characterization of a cannabinoid receptor in rat brain. Molecular Pharmacology 34, 605-613.
31. Devane, W. A., Hanus, L., Breuer, A. et al. (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258, 1946-1949.
32. De Vries, T. J., Homberg, J. R., Binnekade, R., Raaso, H. and Schoffelmeer, A. N. (2003) Cannabinoid modulation of the reinforcing and motivational properties of heroin and heroin-associated cues in rats. Psychopharmacology 168, 164-169.
33. De Vries, T. J., Shaham, Y., Homberg, J. R., Crombag, H., Schuurman, K., Dieben, J., Vanderschuren, L. J. and Schoffelmeer, A. N. (2001) A cannabinoid mechanism in relapse to cocaine seeking. Nature Medicine 7, 1151-1154.
34. Diana, M. A., Levenes, C., Mackie, K. and Marty, A. (2002) Short-term retrograde inhibition of GABAergic synaptic currents in rat Purkinje cells is mediated by endogenous cannabinoids. Journal of Neuroscience 22, 200-208.
35. Diana, M. A. and Marty, A. (2004) Endocannabinoid-mediated short-term synaptic plasticity: depolarization-induced suppression of inhibition (DSI) and depolarization-induced suppression of excitation (DSE). British Journal of Pharmacology 142, 9-19.
36. Di Marzo, V., Fontana, A., Cadas, H., Schinelli, S., Cimino, G., Schwartz, J. C. and Piomelli, D. (1994) Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 372 686-691.
37. Di Marzo, V., Goparaju, S. K., Wang, L. et al. (2001) Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 410, 822-825.
38. Di Marzo, V., Melck, D., Bisogno, T. and De Petrocellis, L. (1998) Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends in Neurosciences 21, 521-528.
39. Dinh, T. P., Carpenter, D., Leslie, F. M., Freund, T. F., Katona, I., Sensi, S. L., Kathuria, S. and Piomelli, D. (2002) Brain monoglyceride lipase participating in endocannabinoid inactivation. Proceedings of the National Academy of Sciences of the United States of America 99, 10819-10824.
40. Egertova, M., Cravatt, B. F. and Elphick, M. R. (2003) Comparative analysis of fatty acid amide hydrolase and cb(1) cannabinoid receptor expression in the mouse brain: evidence of a widespread role for fatty acid amide hydrolase in regulation of endocannabinoid signaling. Neuroscience 119, 481-496.
41. Elphick, M. R. and Egertova, M. (2001) The neurobiology and evolution of cannabinoid signalling. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences 356, 381-408.
42. Fegley, D., Kathuria, S., Mercier, R., Li, C., Goutopoulos, A., Makriyannis, A. and Piomelli, D. (2004) Anandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172. Proceedings of the National Academy of Sciences of the United States of America 101, 8756-8761.
43. Felder, C. C. and Glass, M. (1998) Cannabinoid receptors and their endogenous agonists. Annual Review of Pharmacology and Toxicology 38, 179-200.
44. Felder, C. C., Joyce, K. E., Briley, E. M. et al. (1998) LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulation. Journal of Pharmacology and Experimental Therapeutics 284, 291-297.
45. Fernandez-Ruiz, J., Berrendero, F., Hernandez, M. L. and Ramos, J. A. (2000) The endogenous cannabinoid system and brain development. Trends in Neurosciences 23, 14-20.
46. Freund, T. F., Katona, I. and Piomelli, D. (2003) Role of endogenous cannabinoids in synaptic signaling. Physiological Reviews 83, 1017-1066.
47. Fu, J., Gaetani, S., Oveisi, F. et al. (2003) Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature 425, 90-93.
48. Galiègue, S., Mary, S., Marchand, J., Dussossoy, D., Carrière, D., Carayon, P., Bouaboula, M., Shire, D., Le Fur, G. and Casellas, P. (1995) Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. European Journal of Biochemistry 232, 54-61.
49. Galve-Roperh, I., Sanchez, C., Cortes, M. L., del Pulgar, T. G., Izquierdo, M. and Guzman, M.(2000) Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nature Medicine 6, 313-319.
50. Gaoni, Y. and Mechoulam, R. (1964) Isolation, structure and partial synthesis of an active constituent of hashish. Journal of the American Chemical Society 86, 1646-1647.
51. Gardner, E. L. and Vorel, S. R. (1998) Cannabinoid transmission and reward-related events. Neurobiology of Disease 5, 502-533.
52. 2+ channel current. American Journal of Physiology 276, H2085-2093.
53. Gerdeman, G. L., Ronesi, J. and Lovinger, D. M. (2002) Postsynaptic endocannabinoid release is critical to long-term depression in the striatum. Nature Neuroscience 5, 446-451.
54. Giuffrida, A., Beltramo, M. and Piomelli, D. (2001) Mechanisms of endocannabinoid inactivation: biochemistry and pharmacology. Journal of Pharmacology and Experimental Therapeutics 298, 7-14.
55. Giuffrida, A., Parsons, L. H., Kerr, T. M., Rodriguez de Fonseca, F., Navarro, M. and Piomelli, D. (1999) Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nature Neuroscience 2, 358-363.
56. Gomez, R., Navarro, M., Ferrer, B. et al. (2002) A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. Journal of Neuroscience 22, 9612-9617.
57. Gulyas, A. I., Cravatt, B. F., Bracey, M. H., Dinh, T. P., Piomelli, D., Boscia, F. and Freund, T. F. (2004) Segregation of two endocannabinoid-hydrolyzing enzymes into pre- and postsynaptic compartments in the rat hippocampus, cerebellum and amygdala. European Journal of Neuroscience 20, 441-458.
58. Guzman, M. (2003) Cannabinoids: potential anticancer agents. Nature Reviews Cancer 3, 745-755.
59. Hajos, N., Ledent, C. and Freund, T. F. (2001) Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus. Neuroscience 106, 1-4.
60. Hanus, L., Breuer, A., Tchilibon et al. (1999) HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor. Proceedings of the National Academy of Sciences of the United States of America 96, 14228-14233.
61. Hanus, L., Abu-Lafi, S., Fride, E., Breuer, A., Vogel, Z., Shalev, D. E., Kustanovich, I. and Mechoulam, R. (2001) 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proceedings of the National Academy of Sciences of the United States of America 98, 3662-3665.
62. Herkenham, M., Lynn, A. B., Johnson, M. R., Melvin, L. S., de Costa, B. R. and Rice, K. C. (1991) Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. Journal of Neuroscience 11, 563-583.
63. Hiley, C. R. and Ford, W. R. (2004) Cannabinoid pharmacology in the cardiovascular system: potential protective mechanisms through lipid signalling. Biological Reviews of the Cambridge Philosophical Society 79, 187-205.
64. Hillard, C. J., Manna, S., Greenberg, M. J., DiCamelli, R., Ross, R. A., Stevenson, L. A., Murphy, V., Pertwee, R. G. and Campbell, W. B. (1999) Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1). Journal of Pharmacology and Experimental Therapeutics 289, 1427-1433.
65. Howlett, A. C., Barth, F., Bonner, T. I. et al. (2002) International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacological Reviews 54, 161-202.
66. Howlett, A. C., Bidaut-Russell, M., Devane, W. A., Melvin, L. S., Johnson, M. R. and Herkenham, M. (1990) The cannabinoid receptor: biochemical, anatomical and behavioral characterization. Trends in Neurosciences 13, 420-423.
67. Hungund, B. L. and Basavarajappa, B. S. (2000) Are anandamide and cannabinoid receptors involved in ethanol tolerance? A review of the evidence. Alcohol and Alcoholism 35, 126-133.
68. Hungund, B. L., Basavarajappa, B. S., Vadasz, C., Kunos, G., Rodriguez de Fonseca, F., Colombo, G., Serra, S., Parsons, L. and Koob, G. F. (2002) Ethanol, endocannabinoids, and the cannabinoidergic signaling system. Alcohol: Clinical and Experimental Research 26 565-574.
69. Izzo, A. A., Mascolo, N. and Capasso, F. (2001) The gastrointestinal pharmacology of cannabinoids. Current Opinion in Pharmacology 11, 597-603.
70. Jagerovic, N., Hernández-Folgado, L., Alkorta, I. et al. (2004) Discovery of 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl1h-1,2,4-triazole, a novel in vivo cannabinoid antagonist containing a 1,2,4-triazole motif. Journal of Medicinal Chemistry 47, 2939-2942.
71. Julian, M. D., Martin, A. B., Cuellar, B., Rodriguez de Fonseca, F., Navarro, M., Moratalla, R. and Garcia-Segura, L. M. (2003) Neuroanatomical relationship between type 1 cannabinoid receptors and dopaminergic systems in the rat basal ganglia. Neuroscience 119 309-318.
72. Kathuria, S., Gaetani, S., Fegley, D. et al. (2003) Modulation of anxiety through blockade of anandamide hydrolysis. Nature Medicine 9, 76-81.
73. Kim, J., Isokawa, M., Ledent, C. and Alger, B. E. (2002) Activation of muscarinic acetylcholine receptors enhances the release of endogenous cannabinoids in the hippocampus. Journal of Neuroscience 22, 10182-10191.
74. Kunos, G., Batkai, S., Offertaler, L., Mo, F., Liu, J., Karcher, J. and Harvey-White, J. (2002) The quest for a vascular endothelial cannabinoid receptor. Chemistry and Physics of Lipids 121, 45-56.
75. Ledent, C., Valverde, O., Cossu, G. et al. (1999) Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 283, 401-404.
76. Lichtman, A. H., Leung, D., Shelton, C., Saghatelian, A., Hardouin, C., Boger, D. and Cravatt, B. F. (2004) Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for an unprecedented combination of potency and selectivity. Journal of Pharmacology and Experimental Therapeutics. First published June 30, 2004, doi.10.1 124/jpet.104.069401.
77. Lopez-Rodriguez, M. L., Viso, A., Ortega-Gutierrez, S., Lastres-Becker, I., Gonzalez, S., Fernandez-Ruiz, J. and Ramos, J. A. (2001) Design, synthesis and biological evaluation of novel arachidonic acid derivatives as highly potent and selective endocannabinoid transporter inhibitors. Journal of Medicinal Chemistry 44, 4505-4508.
78. Mackie, K. and Hille, B. (1992) Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proceedings of the National Academy of Sciences of the United States of America 89, 3825-3829.
79. Mackie, K., Lai, Y., Westenbroek, R. and Mitchell, R. (1995) Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. Journal of Neuroscience 15, 6552-6561.
80. Maldonado, R. (2002) Study of cannabinoid dependence in animals. Pharmacology and Therapeutics 95, 153-164.
81. Maldonado, R. and Rodriguez de Fonseca, F. (2002) Cannabinoid addiction: behavioral models and neural correlates. Journal of Neuroscience 22, 3326-3321.
82. Manzanares, J., Corchero, J., Romero, J., Fernandez-Ruiz, J. J., Ramos, J. A. and Fuentes, J. A. (1999) Pharmacological and biochemical interactions between opioids and cannabinoids. Trends in Pharmacological Sciences 20, 287-294.
83. Marsicano, G., Goodenough, S., Monory, K. et al. (2003) CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 302, 84-88.
84. Marsicano, G., Wotjak, C. T., Azad, S. C. et al. (2002) The endogenous cannabinoid system controls extinction of aversive memories. Nature 418, 530-534.
85. Martin, B. R. and Lichtman, A. H. (1998) Cannabinoid transmission and pain perception. Neurobiology of Disease 5, 447-461.
86. Martin, B. R., Sim-Selley, L. J. and Selley, D. E. (2004) Signaling pathways involved in the development of cannabinoid tolerance. Trends in Pharmacological Sciences 25, 325-330.
87. Matsuda, L. A. (1997) Molecular aspects of cannabinoid receptors. Critical Reviews in Neurobiology 11, 143-166.
88. Matsuda, L. A., Bonner, T. I. and Lolait, S. J. (1993) Localization of cannabinoid receptor mRNA in rat brain. Journal of Comparative Neurology 327, 535-550.
89. Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C. and Bonner, T. I. (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346, 561-564.
90. Mauler, F., Mittendorf, J., Horvath, E. and De Vry, J. (2002) Characterization of the diarylether sulfonylester (-)-(R)-3-(2-hydroxymethylindanyl-4-oxy phenyl-4,4,4-trifluoro-1-sulfonate (BAY 38-7271) as a potent cannabinoid receptor agonist with neuroprotective properties. Journal of Pharmacology and Experimental Therapeutics 302, 359-368.
91. Mechoulam, R. (1970) Marihuana chemistry. Science 168, 1159-1166.
92. Mechoulam, R., Ben-Shabat, S., Hanus, L. et al. (1995) Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochemical Pharmacology 50 83-90.
93. Mechoulam, R. and Parker, L. (2003) Cannabis and alcohol - a close friendship. Trends in Pharmacological Sciences 24, 266-268.
94. Molina-Holgado, F., Lledó, A. and Guaza, C. (1997) Anandamide suppresses nitric oxide and TNF-α responses to Theiler's virus or endotoxin in astrocytes. Neuroreport 8, 1929-1933.
95. Munro, S., Thomas, K. L. and Abu-Shaar, M. (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365, 61-65.
96. Navarro, M., Carrera, M. R., Fratta, W. et al. (2001) Functional interaction between opioid and cannabinoid receptors in drug self-administration. Journal of Neuroscience 21, 5344-5350.
97. Navarro, M., Hernandez, E., Munoz, R. M., del Arco, I., Villanua, M. A., Carrera, M. R. and Rodríguez de Fonseca, F. (1997) Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat. Neuroreport 8 491-496.
98. Oka, S., Tsuchie, A., Tokumura, A., Muramatsu, M., Suhara, Y., Takayama, H., Waku, K. and Sugiura, T. (2003) Ether-linked analogue of 2-arachidonoylglycerol (noladin ether) was not detected in the brains of various mammalian species. Journal of Neurochemistry 85, 1374-1381.
99. Okamoto, Y., Morishita, J., Tsuboi, K., Tonai, T. and Ueda, N. (2004) Molecular characterization of a phospholipase D generating anandamide and its congeners. Journal of Biological Chemistry 279, 5298-5305.
100. Pacheco, M., Childers, S. R., Arnold, R., Casiano, F. and Ward, S. J. (1991) Aminoalkylindoles: actions on specific G-protein-linked receptors. Journal of Pharmacology and Experimental Therapeutics 257, 170-183.
101. Panikashvili, D., Simeonidou, C., Ben-Shabat, S., Hanus, L., Breuer, A., Mechoulam, R. and Shohami, E. (2001) An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 413, 527-531.
102. Pertwee, R. G. (2001) Cannabinoid receptors and pain. Progress in Neurobiology 63, 569-611.
103. Piomelli, D. (2003) The molecular logic of endocannabinoid signalling. Nature Reviews Neuroscience 4, 873-884.
104. Piomelli, D., Giuffrida, A., Calignano, A. and Rodríguez de Fonseca, F. (2000) The endocannabinoid system as a target for therapeutic drugs. Trends in Pharmacological Sciences 21, 218-224.
105. Porter, A. C., Sauer, J. M., Knierman, M. D. et al. (2002) Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. Journal of Pharmacology and Experimental Therapeutics 301, 1020-1024.
106. Randall, M. D., Harris, D., Kendall, D. A. and Ralevic, V. (2002) Cardiovascular effects of cannabinoids. Pharmacology and Therapeutics 95, 191-202.
107. Rimondini, R., Arlinde, C., Sommer, W. and Heilig, M. (2002) Long-lasting increase in voluntary ethanol consumption and transcriptional regulation in the rat brain after intermittent exposure to alcohol. The FASEB Journal 16, 27-35.
108. Rinaldi-Carmona, M., Barth, F., Congy, C. et al. (2004) SR147778, a new potent and selective antagonist of the CB1 cannabinoid receptor. Biochemical and pharmacological characterization. Journal of Pharmacology and Experimental Therapeutics 310, 905-914.
109. Rinaldi-Carmona, M., Barth, F., Héaulme, M. et al. (1994) SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Letters 350, 240-244.
110. 2 cannabinoid receptor. Journal of Pharmacology and Experimental Therapeutics 284, 644-650.
111. Robbe, D., Kopf, M., Remaury, A., Bockaert, J. and Manzoni, O. J. (2002) Endogenous cannabinoids mediate long-term synaptic depression in the nucleus accumbens. Proceedings of the National Academy of Sciences of the United States of America 99, 8384-8348.
112. Rodríguez de Fonseca, F., Carrera, M. R., Navarro, M., Koob, G. F., and Weiss, F. (1997) Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal. Science 276, 2050-2054.
113. Rodríguez de Fonseca, F., Del Arco, I., Martin-Calderon, J. L., Gorriti, M. A. and Navarro, M. (1998) Role of the endogenous cannabinoid system in the regulation of motor activity. Neurobiology of Disease 5, 483-501.
114. Rodríguez de Fonseca, F., Navarro, M., Gomez, R., et al. (2001) An anorexic lipid mediator regulated by feeding. Nature 414, 209-212.
115. Rodríguez de Fonseca, F., Roberts, A. J., Bilbao, A., Koob, G. F. and Navarro, M. (1999) Cannabinoid receptor antagonist SR141716A decreases operant ethanol self administration in rats exposed to ethanol-vapor chambers. Zhongguo Yao Li Xue Bao 20, 1109-1114.
116. Rodríguez de Fonseca, F., Rubio, P., Menzaghi, F., Merlo-Pich, E., Rivier, J., Koob, G. F. and Navarro, M. (1996) Corticotropin-releasing factor (CRF) antagonist [D-Phe12,Nle21,38,C alpha MeLeu37]CRF attenuates the acute actions of the highly potent cannabinoid receptor agonist HU-210 on defensive-withdrawal behavior in rats. Journal of Pharmacology and Experimental Therapeutics 276, 56-64.
117. Rueda, D., Navarro, B., Martinez-Serrano, A., Guzman, M., Galve-Roperh, I. (2002) The endocannabinoid anandamide inhibits neuronal progenitor cell differentiation through attenuation of the Rap1/B-Raf/ERK pathway. Journal of Biological Chemistry 277, 46645-46650.
118. Sanchez, C., de Ceballos, M. L., Del Pulgar, T. G. et al. (2001) Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor. Cancer Research 61 5784-5789.
119. Sanchis-Segura, C., Cline, B. H., Marsicano, G., Lutz, B. and Spanagel, R. (2004) Reduced sensitivity to reward in CB1 knockout mice. Psychopharmacology 2004 Apr 9.
120. Schlicker, E. and Kathmann, M. (2001) Modulation of transmitter release via presynaptic cannabinoid receptor. Trends in Pharmacological Sciences 22, 565-572.
121. Schmidt, L. G., Samochowiec, J., Finckh, U., Fiszer-Piosik, E., Horodnicki, J., Wendel, B., Rommelspacher, H. and Hoehe, M. R. (2002) Association of a CB1 cannabinoid receptor gene (CNR1) polymorphism with severe alcohol dependence. Drug and Alcohol Dependence 65, 221-224.
122. Sipe, J. C., Chiang, K., Gerber, A. L., Beutler, E. and Cravatt, B. F. (2002) A missense mutation in human fatty acid amide hydrolase associated with problem drug use. Proceedings of the National Academy of Sciences of the United States of America 99, 8394-8399.
123. Smith, P. F. (2004) Medicinal cannabis extracts for the treatment of multiple sclerosis. Current Opinion in Investigational Drugs 5, 727-730.
124. Stella, N. and Piomelli, D. (2001) Receptor-dependent formation of endogenous cannabinoids in cortical neurons. European Journal of Pharmacology 425, 189-196.
125. Stella, N., Schweitzer, P. and Piomelli, D. (1997) A second endogenous cannabinoid that modulates long-term potentiation. Nature 388, 773-778.
126. Straiker, A., Stella, N., Piomelli, D., Mackie, K., Karten, H. J. and Maguire, G. (1999) Cannabinoid CB1 receptors and ligands in vertebrate retina: localization and function of an endogenous signaling system. Proceedings of the National Academy of Sciences of the United States of America 96, 14565-14570.
127. Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., Yamashita, A. and Waku, K. (1995) 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochemistry Biophysics Research Communications 215, 89-97.
128. Tanda, G. and Goldberg, S. R. (2003) Cannabinoids: reward, dependence, and underlying neurochemical mechanisms - a review of recent preclinical data. Psychopharmacology 169, 115-134.
129. Tarzia, G., Duranti, A., Tontini, A., Piersanti, G., Mor, M., Rivara, S., Plazzi, P. V., Park, C., Kathuria, S. and Piomelli, D. (2003a) Design, synthesis, and structure-activity relationships of alkylcarbamic acid aryl esters, a new class of fatty acid amide hydrolase inhibitors. Journal of Medicinal Chemistry 46, 2352-2360.
130. Tarzia, G., Durand, A., Tontini, A., Spadoni, G., Mor, M., Rivara, S., Plazzi, P. V., Kathuria, S. and Piomelli, D. (2003b) Synthesis and structure-activity relationships of a series of pyrrole cannabinoid receptor agonists. Bioorganic and Medicinal Chemistry 11, 3965-3973.
131. Terranova, J. P., Storme, J. J., Lafon, N., Perio, A., Rinaldi-Carmona, M., Le Fur, G. and Soubrié, P. (1996) Improvement of memory in rodents by the selective CB1 cannabinoid receptor antagonist, SR 141716. Psychopharmacology 126, 165-172.
132. Tsou, K., Mackie, K., Sanudo-Pena, M. C. and Walker, J. M. (1999) Cannabinoid CB1 receptors are localized primarily on cholecystokinin-containing GABAergic interneurons in the rat hippocampal formation. Neuroscience 93, 969-975.
133. Twitchell, W., Brown, S. and Mackie, K. (1997) Cannabinoids inhibit N- and P/Q-type calcium channels in cultured rat hippocampal neurons. Journal of Neurophysiology 78, 43-50.
134. Varma, N., Carlson, G. C., Ledent, C. and Alger, B. E. (2001) Metabotropic glutamate receptors drive the endocannabinoid system in hippocampus. Journal of Neuroscience 21, RC188.
135. Wagner, J. A., Varga, K., Ellis, E. F., Rzigalinski, B. A., Martin, B. R. and Kunos, G. (1997) Activation of peripheral CB1 cannabinoid receptors in haemorrhagic shock. Nature 390, 518-521.
136. Wilson, R. I., Kunos, G. and Nicoll, R. A. (2001) Presynaptic specificity of endocannabinoid signaling in the hippocampus. Neuron 31, 453-462.
137. Wilson, R. I. and Nicoll, R. A. (2001) Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature 410, 588-592.
138. Wilson, R. I. and Nicoll, R. A. (2002) Endocannabinoid signaling in the brain. Science 296, 678-682.
139. Witting, A., Walter, L., Wacker, J., Moller, T. and Stella, N. (2004) P2X7 receptors control 2-arachidonoylglycerol production by microglial cells. Proceedings of the National Academy of Sciences of the United States of America 101, 3214-3219.
140. Zygmunt, P. M., Petersson, J., Andersson, D. A., Chuang, H., Sörgärd, M., Di Marzo, V., Julius, D. and Högestätt, E. D. (1999) Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400, 452-457.